Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Share-based Compensation (2016 - 2025)

Viking Therapeutics' Share-based Compensation history spans 12 years, with the latest figure at $8.6 million for Q4 2025.

  • For Q4 2025, Share-based Compensation rose 51.53% year-over-year to $8.6 million; the TTM value through Dec 2025 reached $40.8 million, up 37.38%, while the annual FY2025 figure was $40.8 million, 37.38% up from the prior year.
  • Share-based Compensation for Q4 2025 was $8.6 million at Viking Therapeutics, up from $7.3 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $13.5 million in Q2 2025 and bottomed at $1.4 million in Q4 2022.
  • The 5-year median for Share-based Compensation is $4.5 million (2023), against an average of $5.1 million.
  • The largest annual shift saw Share-based Compensation soared 130.98% in 2023 before it fell 18.33% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $1.4 million in 2021, then fell by 2.3% to $1.4 million in 2022, then surged by 220.07% to $4.5 million in 2023, then increased by 26.47% to $5.7 million in 2024, then skyrocketed by 51.53% to $8.6 million in 2025.
  • Per Business Quant, the three most recent readings for VKTX's Share-based Compensation are $8.6 million (Q4 2025), $7.3 million (Q3 2025), and $13.5 million (Q2 2025).